Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06378957
Other study ID # IRB00436545
Secondary ID
Status Not yet recruiting
Phase Phase 1
First received
Last updated
Start date September 1, 2024
Est. completion date December 31, 2027

Study information

Verified date April 2024
Source Johns Hopkins University
Contact Austin Zamarripa, PhD
Phone 410-550-6969
Email czamarr2@jhmi.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The current clinical trial will investigate the effects of orally administered d-limonene (limonene), delta-9-tetrahydrocannabinol (THC) and the combination in healthy adult volunteers.


Description:

The current clinical trial will investigate the interaction of orally administered d-limonene (limonene) and delta-9-tetrahydrocannabinol (THC). Limonene is a flavor/fragrance component common to many plants, including cannabis. The investigators have previously demonstrated that vaporized limonene can impact the acute effects of THC. The purpose of this study is to examine whether orally administered limonene modulates the acute effects of orally co-administered THC in a manner similar to when these substances are inhaled A controlled laboratory study will be completed at Johns Hopkins evaluating placebo, THC alone, and four ascending doses of d-limonene in combination with THC. Participants will be healthy adults with experience using cannabis. A total of 6 outpatient drug administration sessions will be conducted for each evaluable participant. The investigators will recruit study volunteers until 20 participants complete the protocol.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 65
Est. completion date December 31, 2027
Est. primary completion date July 1, 2027
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: - Have provided written informed consent - Be between the ages of 18 and 55 - Be in good general health based on a physical examination, medical history, vital signs, and screening urine and blood tests - Test negative for drugs of abuse other than cannabis, including breath alcohol at the screening visit and at clinic admission - Not be pregnant or nursing (if female). All females must have a negative serum pregnancy test at the screening visit and a negative urine pregnancy test at clinic admission. - Have a body mass index (BMI) in the range of 18 to 36 kg/m2 - Blood pressure at Screening Visit does not exceed a systolic blood pressure (SBP) of 150 mmHg or a diastolic blood pressure (DBP) of 90 mmHg - Have no allergies to any of the ingredients used to prepare (cellulose, THC, d-limonene). - Report having used a high THC cannabis product in the past 3 years and having experienced anxiety after consuming cannabis at least once in lifetime. Exclusion Criteria: - Non-medical use of psychoactive drugs other than, nicotine, alcohol, or caffeine 3 month prior to the Screening Visit; - History of or current evidence of significant medical (e.g. seizure disorder) or psychiatric illness (e.g. psychosis) judged by the investigator to put the participant at greater risk of experiencing an adverse event due to exposure or completion of other study procedures. - Use of an over the counter (OTC), systemic or topical drug(s), herbal supplement(s), or vitamin(s) within 14 days of experimental sessions; which, in the opinion of the investigator or sponsor, will interfere with the study result or the safety of the subject. - Use of a prescription medication (with the exception of birth control prescriptions) within 14 days of experimental sessions; which, in the opinion of the investigator or sponsor, will interfere with the study result or the safety of the subject. - Average use of cannabis more than 2 times per week in the prior 3 months. - History of clinically significant cardiac arrhythmias or vasospastic disease (e.g., Prinzmetal's angina). - Enrolled in another clinical trial or have received any drug as part of a research study within 30 days prior to dosing. - Individuals with anemia or who have donated blood in the prior 30 days

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
D-Limonene
Oral Limonene administered via capsule
Delta-9-THC
Oral delta-9-THC in ethanol vehicle administered via capsule
Placebo
Placebo (cellulose) administered via capsule

Locations

Country Name City State
United States Johns Hopkins Behavioral Pharmacology Research Unit Baltimore Maryland

Sponsors (2)

Lead Sponsor Collaborator
Johns Hopkins University National Institutes of Health (NIH)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Subjective Drug Effect as assessed by Visual Analog Scale Subjective drug effect will be measured on a 100 point visual analog scale (VAS) where 0 = no drug effect and 100 = strongest drug effect imaginable 8 hours after dosing
Secondary Subjective Drug Liking as assessed by Visual Analog Scale Subjective drug liking will be measured on a 100 point visual analog scale (VAS) where 0 = no drug effect and 100 = strongest drug effect imaginable 8 hours after dosing
Secondary Subjective anxiety as assessed by Visual Analog Scale Subjective anxiety will be measured on a 100 point visual analog scale (VAS) where 0 = no drug effect and 100 = strongest drug effect imaginable 8 hours after dosing
Secondary Subjective hunger as assessed by Visual Analog Scale Subjective hunger will be measured on a 100 point visual analog scale (VAS) where 0 = no drug effect and 100 = strongest drug effect imaginable 8 hours after dosing
Secondary Subjective paranoia as assessed by Visual Analog Scale Subjective paranoia will be measured on a 100 point visual analog scale (VAS) where 0 = no drug effect and 100 = strongest drug effect imaginable 8 hours after dosing
See also
  Status Clinical Trial Phase
Completed NCT04976738 - A Study of Cybis™ 10:25 THC:CBD Oil in Adults With Chronic Back/Neck Pain Phase 1/Phase 2
Active, not recruiting NCT03560934 - Tetrahydrocannabinol (THC) and Sleep Early Phase 1
Not yet recruiting NCT05999383 - Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration Phase 2
Recruiting NCT04429568 - THC Crossover Study N/A
Completed NCT04130633 - Behavioral Pharmacology of THC and Alpha-pinene Phase 1
Completed NCT05121506 - A Study to Investigate the Bioavailability and Skin Absorption of CBD and THC From GT4 Technology in Healthy Adults Phase 1
Completed NCT04360044 - Efficacy of Inhaled Cannabis for Acute Migraine Treatment Phase 2
Withdrawn NCT04340700 - Characterization of the Pharmacodynamic Response to Vaped THC Phase 3
Not yet recruiting NCT06099379 - Modulation of THC Effects by CBD: a Dose-ranging Study Phase 1/Phase 2
Completed NCT04851392 - Do Adolescents and Adults Differ in Their Acute Response to Cannabis? N/A
Completed NCT04294966 - Age-Related Effects of THC Early Phase 1
Recruiting NCT05116527 - THC Memory & Reward Learning Pilot Phase 1/Phase 2
Recruiting NCT05514899 - Effects of Cannabidiol and Tetrahydrocannabinol on Microbiome and Neuroinflammation in HIV Phase 2
Not yet recruiting NCT03098940 - A Bioavailability Study on Dronabinol Phase 1
Active, not recruiting NCT02102113 - Probing the Cannabinoid System in Individuals With a Family History of Psychosis Early Phase 1
Not yet recruiting NCT06077292 - Cannabis THC Potency, Metabolism, and Cognitive Impairment in Young Adults N/A
Suspended NCT05427630 - Dose-Ranging Trial of Inhaled Cannabis for Acute Migraine Treatment Phase 2
Not yet recruiting NCT05641766 - Multimodal Magnetoencephalography and Electroencephalography Exploration of the Acute Effects of THC Exposure on Neural Noise and Information Transmission Within Working Memory Networks Phase 2